Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson’s Abiraterone Drug For Prostate Cancer
November 29, 2010
PharmaWire reported on November 29, 2010 that the patent life of BTG and Johnson & Johnson’s potential prostate cancer blockbuster abiraterone is unclear due to laws changed in 1995 for calculating expiration dates. According to BTG, abiraterone is protected until 2024. Although abiraterone is a simple molecule that will be reproduced by generic companies very easily and the drug may have a short patent life relying on data exclusivity, experts believe the data is still striking enough to secure a large market share in this timeframe. The companies are expected to also file for an extension of the patent for up to five years. However, patents covering manufacturing and synthesis methods typically cannot be enforced against generic applicants until shortly prior to commercial launch, Matthew Becker, a patent attorney at Axinn, noted in the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
